Innovations in IBD Management: Novel Therapies and their Role in Achieving Treatment Targets

Released On
July 3, 2019

Expires On
July 2, 2020

Media Type
Internet

Completion Time
60 minutes

Specialty
Gastroenterology

Topic(s)
IBD

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Boston University School of Medicine.

 

Supported by an independent educational grant from Celgene Corporation.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 contact hours, which is eligible for pharmacology credit

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of gastroenterologists, pediatric gastroenterologists, surgeons, radiologists, pathologists, primary care physicians, nurse practitioners, physician assistants, nurses, and other allied healthcare providers involved in the diagnosis and management of inflammatory bowel disease.

Program Overview

This enduring audio-activity reviews the best practices for incorporating targets of mucosal healing into treatment strategies for patients with IBD, therapeutic drug monitoring and biomarker assessment, and timely education on newer agents for IBD treatment. The didactic presentation is centered around a patient case and includes video vignettes of an actual patient sharing his concerns regarding IBD treatment.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe targets of mucosal healing used in treat-to-target strategies and the evidence that exists to support the use of these strategies in IBD patients.
  • Design personalized treatment plans for patients with IBD that will improve patient outcomes and decrease heterogeneity that exists in the treatment of IBD.
  • Examine novel agents for IBD in terms of therapeutic target, safety and efficacy data, and place in therapy.

Faculty

FACULTY NAME and TITLE

Francis A. Farraye, MD, MSc

Course Director
Senior Associate Consultant
Division of Gastroenterology and Hepatology
Director, Inflammatory Bowel Disease Center
Mayo Clinic, Jacksonville Florida

FACULTY NAME and TITLE

Alan C. Moss, MD, FACG, FEBG, AGAF, FRCPI

Director of Translational Research
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School

Physician Accreditation Statement

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

Boston University School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

CNE Contact Hours: 1, which is eligible for pharmacology credit.

Disclosures of Conflicts of Interest

Accreditor Disclosure of Conflicts of Interest Policy:
Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Dr. Farraye

  • Consultant: Braintree Laboratories, Ferring Pharmaceuticals, Janssen Biotech, Inc., Merck & Co. Inc., Pfizer Inc., and Takeda Pharmaceuticals, USA, Inc.
  • Stockholder: Innovation Pharmaceuticals
  • Advisory Board: Innovation Pharmaceuticals
  • Data Safety Monitoring Board : Eli Lilly and Company.

Dr. Alan Moss

  • Consultant: Janssen Biotech Inc., Theravance Biopharma, and Seres Therapeutics, Inc.

Accreditor Disclosures:

Michael Burk, Senior Program Manager, Boston University School of Medicine Continuing Medical/Nursing Education Office, has no relevant financial relationships to disclose.

Dana Frazier, Program and Grant Manager, Boston University School of Medicine Continuing Medical/Nursing Education Office, has no relevant financial relationships to disclose.

Bret Lashner, MD, CME Co-Course Director, Boston University School of Medicine Continuing Medical/Nursing Education Office and Professor of Medicine at the Cleveland Clinic, has no relevant financial relationships to disclose.

Beth-Ann Norton is a consultant for Takeda Pharmaceuticals, USA, Inc.

Laura Stinson, consultant medical editor, Boston University School of Medicine Continuing Medical/Nursing Education Office, has no relevant financial relationships to disclose.

Carmela Townsend, Lead Nurse Planner, Boston University School of Medicine Continuing Medical/Nursing Education Office, has no relevant financial relationships to disclose.

Method of Participation

Participation in this activity is free. By reviewing the course content and successfully completing the intra-activity questions and evaluation, physicians are entitled to receive 1 AMA PRA Category 1 Credit(s)™ and nurses are entitled to receive 1 contact hour. To receive credit, participants must:

  • Participate in the activity and review all content.
  • Complete the post-test and activity evaluation.
  • Score 70% or higher on the post-test to receive credit for this activity. You are limited to 5 post-test attempts.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
  • Certificates will be available for download upon completion of the activity.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure of Unlabeled Use

The faculty members do plan on discussing the unlabeled/investigational uses abrilumab, brazilumab, etrolizumab, filgotinib, guselkumab, methotrexate, mirikizumab, natalizumanb, risankizumab, thiopurines, and upadacitnib in the treatment of IBD. All medications are not indicated by the FDA for IBD treatment.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

For questions about this activity, please contact cme@bu.edu or www.bu.edu/cme

Boston University School of Medicine Privacy Policy

© Trustees of Boston University, 2019